Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M

Arcutis Biotherapeutics, Inc.

2023-Q3 EPS reported -$3.19 revenue$46,080,000

Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.
ZORYVE plaque psoriasis prescriptions over 110k from nearly 9k prescribers; FDA approved expanded indication to children ages 6+.
sNDA submitted for roflumilast cream 0.15% for atopic dermatitis ages 6+; potential approval Q3 2024.
Completed $100M public offering in Oct 2023; amended SLR debt facility removing market cap covenant, requires $31M additional capital by Apr 2024.
Appointed Todd Edwards CCO and John Smither interim CFO; Huadong collaboration upfront $30M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported quarter ended September 30, 2023 results: revenue net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million.

Period: quarter ended September 30, 2023
Revenue: net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million
Result: reported results

Exact text from the filing

2023 Financial Results and Provides Business Update • Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.